Medicine guide

Dabigatran Etexilate

150 mg · Capsule

  • Prescription only
  • Direct Thrombin Inhibitor
Active substance
Dabigatran Etexilate
Made by
Camber Pharmaceuticals, Inc.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupBlood, clotting and anaemia

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (DABIGATRAN). It describes the substance, not this exact product.

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors.

Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus.

Half-life12–17 h
Mostly cleared after≈ 3 daysfive half-lives — our arithmetic
How the body breaks it down

Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and dabigatran have similar pharmacological activity.

How it leaves the body

Dabigatran is eliminated primarily in the urine.

With food

Coadministration of dabigatran with a high-fat meal delays the time to C max by approximately 2 hours but has no effect on the bioavailability of dabigatran; Dabigatran may be administered with or without food.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-13

Safety of the active substance

From the US prescribing label for the same active substance (DABIGATRAN). It describes the substance, not this exact product.

Serious warning

WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including dabigatran, increases the risk of thrombotic events.

Must not be used by
  • Dabigatran is contraindicated in patients with:.
  • Active pathological bleeding [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.1 )].
  • History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions ( 6.1 )].
  • Mechanical prosthetic heart valve [see Warnings and Precautions ( 5.4 )].
Most common side effects

The most frequent adverse reactions leading to discontinuation of dabigatran etexilate capsules were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

Details

Made byCamber Pharmaceuticals, Inc.
Active substanceDabigatran Etexilate
Used inBlood, clotting and anaemia
Strength150 mg
FormCapsule
RouteOral
Packs10 BLISTER PACK in 1 CARTON / 6 CAPSULE in 1 BLISTER PACK · 60 CAPSULE in 1 BOTTLE
NDC31722-622

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Other strengths and forms

31 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.